Tag Archive for: Cancer

IO Biotech Announces Participation in Upcoming Investor Conferences

/in

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event: Jefferies London Healthcare Conference Location: London One-on-one meetings: Wednesday, November 15, 2023 Participants: Mai-Britt Zocca, PhD, President and […]

Read more

iOnctura to Present Research on Roginolisib and IOA-359 at ASH

/in

Three abstracts accepted by ASH with two poster presentations Geneva, Switzerland and Amsterdam, The Netherlands, 3 November 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces abstract data to be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San […]

Read more

Poolbeg Pharma plc – POLB 001 Data to be Presented at American Society of Hematology Annual Meeting

/in

Potential to address cancer treatment related Cytokine Release Syndrome 3 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that an abstract detailing POLB 001’s promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at 65th American […]

Read more

STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer

/in

1 November 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce the appointment of Marguerite Hutchinson, J.D., as Chief Business Officer. Read more…

Read more

iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ

/in

Roginolisib is in development for solid and hematologic malignancies including uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 31 October 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that the US Food and Drug Administration (FDA) has granted permission to proceed […]

Read more
© Optimum Strategic Communications.